Open main menu

Disufenton sodium

  (Redirected from NXY-059)

Disufenton sodium (NXY-059, Cerovive) is the disulfonyl derivative of the neuroprotective spin trap phenylbutylnitrone or "PBN". It was under development at the drug company AstraZeneca. A 2005 phase-3 clinical trial[1][2] called "SAINT-1" reported some efficacy in the acute treatment of ischemia injury due to stroke. However, a 2006 attempt to repeat this trial indicated no significant activity. After ruling out other causes, the authors tentatively attributed the positive results in the first trial to "chance".[1] AstraZeneca then terminated the development programme.[3] PBN and its derivatives hydrolyze and oxidize in vitro to form respectively MNP-OH (AKA, NtBHA) and its parent spin-trap MNP.

Disufenton sodium
Disufenton sodium.png
Clinical data
ATC code
  • none
PubChem CID
Chemical and physical data
Molar mass381.33 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)


  1. ^ a b Lees, Kennedy R.; Zivin, Justin A.; Ashwood, Tim; Davalos, Antonio; Davis, Stephen M.; Diener, Hans-Christoph; Grotta, James; Lyden, Patrick; et al. (2006). "NXY-059 for Acute Ischemic Stroke". New England Journal of Medicine. 354 (6): 588–600. doi:10.1056/NEJMoa052980. PMID 16467546.
  2. ^ Lees, KR; Davalos, A; Davis, SM; Diener, HC; Grotta, J; Lyden, P; Shuaib, A; Ashwood, T; et al. (2006). "Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial". Stroke: A Journal of Cerebral Circulation. 37 (12): 2970–8. doi:10.1161/01.STR.0000249410.91473.44. PMID 17068304.
  3. ^ Renovis: Press Release Archived October 28, 2006, at the Wayback Machine

External linksEdit